Synergistic activity of vancomycin and teicoplanin alone and in combination with streptomycin against Enterococcus faecalis strains with various vancomycin susceptibilities

International Journal of Antimicrobial Agents

Volumn 23, Issue 4, 2004, Pages 343-348

  Babalola, Chinedum P ^a   Patel, Kalpana B ^a   Nightingale, Charles H ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

Enterococcus faecalis; Streptomycin; Synergy; Teicoplanin; Vancomycin

Indexed keywords

GLYCOPEPTIDE; STREPTOMYCIN; TEICOPLANIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; DRUG POTENTIATION; ENTEROCOCCUS FAECALIS; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; DRUG SYNERGISM; ENTEROCOCCUS FAECALIS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; STREPTOMYCIN; TEICOPLANIN; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 1842789190     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2003.09.017     Document Type: Article

References (37)

1. Jett B.B., Huycke M.M., Gilmore M.S. Virulence of enterococci. Clin. Microbiol. Rev. 7:1994;462-478.
2. Johnson A.P. The pathogenicity of enterococci. J. Antimicrob. Chemother. 33:1994;1083-1089.
3. Schaberg DR, Culver DH, Gaynes RP. Major trends in the microbial etiology of nosocomial infection. Am J Med 1991;91(3B):72S-5S.
4. Dupre I., Zanett S., Schito A.M., Fadda G., Sechi L.A. Incidence of virulence determinations in clinical and Enterococcus faecalis isolates collected in Sardina (Italy). J. Med. Microbiol. 52:2003;491-498.
5. Jones RN, Sader HS, Erwin ME, Anderson SC and the Enterococcus Study Group. Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Diagn Microbiol Infect Dis 1995;21:85-93.
6. Eliopoulos G.M., Wennersten C.B., Gold H.S., Schulin T., Souli M., Farris M.G.et al. Characterization of vancomycin-resistant Enterococcus faecium isolates from United States and their susceptibility in vitro to dalfopristin-quinupristin. Antimicrob. Agents Chemother. 42:1998;1088-1092.
7. Auckland C., Treare L., Cooke F. Linezolid-resistant enterococci: report of the first isolates in the United Kingdom. J. Antimicrob. Chemother. 50:2002;743-746.
8. Marshall S.H., Donsky C.J., Hutton-Thomas R., Salata R.A., Rice L.B. Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis. Antimicrob. Agents Chemother. 46:2002;3334-3336.
9. Kawalec M., Gniadkowski M., Kedzierska J., Skotnicki A., Fiett J., Hryniewicz W. Selection of teicoplanin-resistant Enterococcus faecium mutant during an outbreak caused by vancomycin-resistant enterococci with vanB phenotype. J. Clin. Microbiol. 39:2001;4274-4282.
10. Thauvin C., Eliopoulos G.M., Willey S., Wennerstein C., Moellering R.C. Jr. Continuous-infusion ampicillin therapy of enterococcal endocarditis in rats. Antimicrob. Agents Chemother. 31:1987;139-143.
11. Lavoie S.R., Wong E.S., Coudron P.E., Williams D.S., Markowtz S.M. Comparison of ampicillin-sulbactam with vancomycin for treatment of experimental endocarditis due to a β-lactamase-producing, highly gentamicin-resistant isolate of Enterococcus faecalis. Antimicrob. Agents Chemother. 37:1993;1447-1451.
12. Leclercq R., Bingen E., Su Q.H., Lambert-Zechovski N., Courvalin P., Duval J. Effects of combinations of β-lactams, daptomycin, gentamicin, and glycopeptides against glycopeptide-resistant enterococci. Antimicrob. Agents Chemother. 35:1991;192-198.
13. Hayden M.K., Koeig G.I., Trenholme G.M. Bactericidal activities of antibiotics against vancomycin-resistant Enterococcus faecium blood isolates and synergistic activities of combinations. Antimicrob. Agents Chemother. 38:1994;1225-1229.
14. Green M., Barbadora K., Wadowsky R.M. Simple test of synergy between ampicillin and vancomycin for resistant strains of Enterococcus faecium. J. Clin. Microbiol. 32:1994;2837-2839.
15. Nicolau D.P., Marangos M.N., Nightingale C.H., Patel K.B., Cooper B.W., Quintiliani R. Jr.et al. Efficacy of vancomycin and teicoplanin alone and in combination with streptomycin in experimental, low-level vancomycin-resistant, vanB-type Enterococcus faecalis endocarditis. Antimicrob. Agents Chemother. 40:1996;55-60.
16. Ravizzola G., Cabibbo E., Peroni L., Longo M., Pollara P.C., Corulli M.et al. In-vitro study of synergy between β-lactam antibiotics and glycopetides against enterococci. J. Antimicrob. Chemother. 39:1997;461-470.
17. Baltch A.L., Smith R.P., Pitz W.J., Bopp L.H. Inhibitory and bactericidal effects of telithromycin (HMR 3647, RU 56647) and five comparative antibiotics, used singly and in combination. Chemotherapy. 47:2001;250-260.
18. Reynolds P. Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Eur. J. Clin. Microbiol. Infect. Dis. 8:1989;943-950.
19. Bibler M.R., Frame P.T., Hagler D.N., Bode R.B., Staneck J.L., Thamlikitkul V.et al. Clinical evaluation of efficacy, pharmacokinetics, and safety of teicoplanin for serious gram-positive infections. Antimicrob. Agents Chemother. 31:1987;207-212.
20. Fines M., Perichion B., Reynolds P., Salim D.F., Courvalin P. vanE, a new type of acquired glycopeptide resistance in Enterococcus faecalis BM 4405. Antimicrob. Agents Chemother. 43:1999;2161-2164.
21. Quintiliani R. Jr., Evers S., Courvalin P. The vanB gene confers various levels of self-transferable resistance to vancomycin in enterococci. J. Infect. Dis. 167:1993;1220-1223.
22. Dutka-Malin S., Leclercq R., Coutant V., Duval J., Courvalin P. Phenotypic and genotypic heterogenicity of glycopeptide resistance determinations in gram-positive bacteria. Antimicrob. Agents Chemother. 34:1990;1875-1879.
23. Quintiliani R. Jr., Courvalin P. Conjugal transfer of vancomycin-resistance determinant vanB between enterococci involves the movement of large genetic elements from chromosome to chromosome. FEMS Microbiol. Lett. 119:1994;359-364.
24. Donskey C.J., Schreiber J.R., Jacobs M.R., Shekar R., Salata R.A., Gordon S.et al. A polyclonal outbreak of predominantly vanB vancomycin-resistant enterococci in northeast Ohio. Northeast Ohio Vancomycin-Resistant Enterococcus Surveillance program. Clin. Infect. Dis. 29:1999;573-579.
25. Kawelec M., Gniadkowski M., Zielinska U., Klos W., Hryniewicz W. A vancomycin resistant-Enterococcus faecium strain carrying the vanB2 gene variant in a Polish hospital. J. Clin. Microbiol. 39:2001;811-815.
26. Kawelec M., Gniadkowski M., Zaleska M., Ozorowski T., Konopka L., Hryniewicz W. Outbreak of vancomycin-resistant Enterococcus faecium of the phenotype vanB in a hospital in Warsaw, Poland: probable transmission of the resistance determinants into an endemic vancomycin-susceptible strain. J. Clin. Microbiol. 39:2001;1781-1787.
27. National Committee for Clinical Laboratory Standards (NCCLS). Methods for dilution of antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard. NCCLS, Wayne Pa. 2000.
28. Aeschliman J.R., Zervos M.J., Rybak M.J. Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin- dalfopristin) administration by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulated endocardial vegetation. Antimicrob. Agents Chemother. 42:1998;2710-2717.
29. Matsumura S.O., Louie L., Louie M., Simor A.E. Synergy testing of vancomycin-resistant Enterococcus faecium against quinupristin-dalfopristin in combination with other antimicrobial agents. Antimicrob. Agents Chemother. 43:1999;2776-2779.
30. Allen G.P., Cha R., Rybak M.J. In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials against multi-drug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 46:2002;2606-2612.
31. Eliopoulos G.M., Wennersten C.B. Antimicrobial activity of quinupristin-dalfopristin combined with other antibiotics against vancomycin-resistant enterococci. Antimicrob. Agents. Chemother. 46:2002;1319-1324.
32. Greenwood D. Microbiological properties of teicoplanin. J. Antimicrob. Chemother. 21:1988;1-13.
33. Gorzynski E.A., Amsterdam D., Beam T.R. Jr., Rotstein C. Comparative in vitro activities of teicoplanin, vancomycin, oxacillin, and other antimicrobial agents against bacteremic isolates of gram-positive cocci. Antimicrob. Agents Chemother. 33:1989;2019-2022.
34. Hoepfl A.W. Overview of synergy with reference to double beta-lactam combinations. DICP Ann. Pharmacother. 25:1991;972-977.
35. Al-Obeid S., Billot-Klein D., van Heijenoort J., Collatz E., Gutmann L. Replacement of essential penicillin binding proteins by high-molecular mass PBB, may explain vancomycin-β-lactam synergy in low-level vancomycin-resistant Enterococcus faecium D366. FEMS Microbiol. Lett. 91:1992;879-884.
36. Gutmann L., Al-Obeid S., Billot-Klein D., Guerrier M., Collatz E. Synergy and resistance to synergy between β-lactam antibiotics and glycopeptide-resistant strains of Enterococcus faecium. Antimicrob. Agents Chemother. 38:1994;824-829.
37. 14C -labelled streptomycin by Enterococci J. Clin. Invest. 50:1971;2580-2584.